Home » Stocks » XOMA

XOMA Corporation (XOMA)

Stock Price: $37.10 USD 0.90 (2.49%)
Updated Mar 1, 2021 4:00 PM EST - Market closed
Market Cap 409.14M
Revenue (ttm) 2.23M
Net Income (ttm) -12.71M
Shares Out 11.02M
EPS (ttm) -1.26
PE Ratio n/a
Forward PE 714.29
Dividend n/a
Dividend Yield n/a
Trading Day March 1
Last Price $37.10
Previous Close $36.20
Change ($) 0.90
Change (%) 2.49%
Day's Open 36.77
Day's Range 36.13 - 38.01
Day's Volume 19,028
52-Week Range 14.14 - 46.32

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

EMERYVILLE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the following upcoming investor con...

Seeking Alpha - 1 month ago

XOMA has built a large portfolio of drug royalties, over 65, with the potential to build a biotechnology business with high upside but limited and diversified downside protection. This royalty...

GlobeNewsWire - 1 month ago

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:

GlobeNewsWire - 2 months ago

EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced underwritten registered ...

GlobeNewsWire - 2 months ago

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 88...

GlobeNewsWire - 2 months ago

EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of s...

Zacks Investment Research - 2 months ago

XOMA saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

GlobeNewsWire - 3 months ago

EMERYVILLE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $2 million milestone payment from Takeda Pharmac...

GlobeNewsWire - 3 months ago

EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $1 million milestone payment from Agenus Inc. (N...

Zacks Investment Research - 3 months ago

As of late, it has definitely been a great time to be an investor in XOMA.

Zacks Investment Research - 3 months ago

Xoma (XOMA) delivered earnings and revenue surprises of 52.38% and -75.78%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

Company recently earned a $ 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering...

GlobeNewsWire - 3 months ago

EMERYVILLE, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technol...

GlobeNewsWire - 4 months ago

EMERYVILLE, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 d...

GlobeNewsWire - 4 months ago

EMERYVILLE, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned $1.9 million in payments from two partners. The Co...

GlobeNewsWire - 5 months ago

EMERYVILLE, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:

Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor in XOMA.

Zacks Investment Research - 6 months ago

Xoma (XOMA) delivered earnings and revenue surprises of 13.16% and -74.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

Partners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts Partners continue to advance clinical assets within the ...

GlobeNewsWire - 6 months ago

Live video feed will be available on XOMA’s website Live video feed will be available on XOMA’s website

Zacks Investment Research - 7 months ago

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 8 months ago

EMERYVILLE, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today Natasha A. Hernday, Senior Vice President, Corporate Development at Seattle Genetics, In...

GlobeNewsWire - 8 months ago

EMERYVILLE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) today announced the Company has been added to the Russell 2000® and Russell 3000® Indexes following the ...

Zacks Investment Research - 8 months ago

XOMA (XOMA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Investment Research - 9 months ago

Xoma (XOMA) delivered earnings and revenue surprises of -206.25% and -76.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 11 months ago

Zydus gains exclusive rights to develop and commercialize XOMA’s IL-2 antibody Zydus gains exclusive rights to develop and commercialize XOMA’s IL-2 antibody

Zacks Investment Research - 1 year ago

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in XOMA.

GlobeNewsWire - 1 year ago

Raises $22 million from existing stockholders Raises $22 million from existing stockholders

Zacks Investment Research - 1 year ago

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

Other stocks mentioned: CHRS, MGTX, MRNA, QURE
The Motley Fool - 1 year ago

Why you should keep an eye on these potential outperformers this month.

Other stocks mentioned: CASY, CTAS, XOM
GlobeNewsWire - 1 year ago

EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candid...

GlobeNewsWire - 1 year ago

EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to r...

GlobeNewsWire - 1 year ago

EMERYVILLE, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its intent to commence a rights offering pursuant to which th...

Zacks Investment Research - 1 year ago

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

Includes royalty interest in NIR178 Includes royalty interest in NIR178

GlobeNewsWire - 1 year ago

EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will provide a corporate update at the 2019 Cant...

GlobeNewsWire - 1 year ago

EMERYVILLE, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s busin...

Zacks Investment Research - 1 year ago

Xoma (XOMA) delivered earnings and revenue surprises of 14.55% and 52.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Xoma (XOMA) delivered earnings and revenue surprises of 261.54% and 152.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Motley Fool - 1 year ago

After years of decline, spending on offshore oil projects is on track to bounce back in 2019.

Other stocks mentioned: CLB, ESV, HES, OII, XOM

About XOMA

XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for... [Read more...]

Industry
Biotechnology
CEO
James R. Neal
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
XOMA
Full Company Profile

Financial Performance

In 2019, XOMA's revenue was $18.37 million, an increase of 246.67% compared to the previous year's $5.30 million. Losses were -$1.98 million, -85.15% less than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for XOMA stock is "Buy." The 12-month stock price forecast is 46.00, which is an increase of 23.99% from the latest price.

Price Target
$46.00
(23.99% upside)
Analyst Consensus: Buy